Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T1695 vs Ciclosporin in Moderate to Severe Vernal Keratoconjunctivitis
NCT07169695Phase 2Recruiting
- Sponsor
- Laboratoires Théa
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of T1695 in Vernal Keratoconjunctivitis (VKC), sponsored by Laboratoires Théa. Started Mar 2026; status: recruiting.
02
Drugs
T1695
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on NCT07169695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169695.